前苏联专利SU786899A3 Method of preparing derivatives of 1-(1,3-dioxolan-2-yl-methyl)-1h-imidazoles or -1h-1,2,4-triazoles

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles and 1H-1,2,4-triazoles useful as antifungal and antibacterial agents.
公开号:SU786899A3
申请号:SU782570553
申请日:1978-01-30
公开日:1980-12-07
发明作者:Херес Ян；Жакобус Жозеф Баккс Лео；Эктор Мостман Жозеф
申请人:Жансен Фармасетика Н.В. (Фирма)；
IPC主号:

专利说明:

benzoyl or substituted benzyl with 1-2 substituents representing independently halogen, lower alkyl or lower alkyloxy R - hydrogen atom or nitro group independently of each other, provided that if it is a nitro group, then A group is an amino group, or their acid additive salts, in the form of a mixture or individual stereoisomers. The compounds of general formula 1 possess biological activity and can be used in medicine. A known method for producing 1, 3-dioxolan-2-ylmethylimide azole derivatives of the general formula O. 1G V 1) where Ar is phenyl, mono-di or tri-halophenyl, lower alkyl phenyl or lower alkoxy 5 nil; phenyl, substituted phenyl, which contains 1–3 substituents of the group: halogen, lower alkyl, lower alkoxy, cyphenyl or benzyl j onLyl or halo-naphthyl, oxygen, sulfur or methyl, 0.1, or their acid addition salts as a mixture or individual stereoisors possessing antimicrobial activity, which implies that the imidazole sodium salt is reacted with a compound of the total. Formulas: w-dHg- Ar AG- (X (1 H2) "- f - halogen, tosylate; Ar, Ar, X and n have the indicated values; in dimethylformamide in the presence of sodium iodide at an elevated temperature ij obtaining new compounds that expand the arsenal of means of influencing a living organism. This goal is achieved by the present method of producing compounds. General formula D, which consists in that the compound of the general formula AND CHg dHj-w where Q and Ar have the indicated values; V / - halogen, methylsulphonyloxy- or 4-methylphenylsulfonyloxygroup is subjected, the interaction action with a compound of the general formula W: where A and T have the indicated meanings, in an inert organic solvent, preferably in the presence of a base, at elevated temperature. The process is carried out, preferably, at 100-130 C. The base is potassium carbonate, potassium hydroxide. M, N-dimethylformamide, dimethyl sulfoxide, benzene, 1,4-dioxane are used as inert organic solvents. The examples below illustrate the invention. Example 1. A mixture of 2.4 h; N- (4-hydroxyphenyl) benzamide, 4.2 h, cis-2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-ylmethylmethanesulfonate, 2 h, potassium carbonate and 75 h, dimethyl sulfoxide is stirred overnight at. The reaction mixture is then cooled and poured into water. The product is extracted twice with trichloromethane. The combined extracts are washed twice with water, dried, filtered and evaporated. The residue is crystallized from 1-butanol. The product is filtered off and dried, get 2.7 h (51%) CIS-N-4- 2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolane-4 - methyl methoxy phenyl benzamide with a melting point of 217.6 ° C. Example 2. According to the procedure of Example 1, using an equivalent amount of the appropriately substituted N- (4-hydroxyphenyl) benzamide as the starting material, the following compounds are obtained: cis-M- | 4- (2- (2,4-dichlorophenyl) - 2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-ylmethoxy-phenyl} -4-methoxybenzamide with mp 188, cis-N-4- 2- (2, 4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-ylmethoxy-phenyl-4-fluorobenzamide with mp 198.2 ° C; cis-ethyl (2,4-dichlorophenyl) - 2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-ylmethoxy-phenyl | -carbonate with mp 178, and cis-4-bromo-M-4- 2- (2, 4-dichlorophenyl) -2- (1H-them Dazol-1-ylmethyl) -1,3-dioxolan-4-ylmethoxy-phenylbenzamide with mp 217, Example 3. Mixture 2.8 parts of 4-chloro-N- (4-hydroxyphenyl) -benzamide , 0.4 h, 78% dispersion of ntri hydride, 15 parts of dimethyl sulfoxide and 18 benzene are stirred for 1 hour at 40 C. Then 4.2 parts of cis -2- (2,4-dichlorophenyl) are added -2-1H-imidazbl-1-ylmethyl-1, 3-dioxole an-4-ylmethyl-methanesulfonate and the mixture is stirred overnight at 100 ° C. Pea; Cool the mixture and drink water. The product is extracted twice with benzene. The combined extras are washed with water, dried and evaporated. The residue is crystallized from 1-butacol. The product is filtered and dried, yielded 3.2 h, (58%) cis-4-chloro-m-4-1.2- (2,4- di.chlorophenyl) -2- (H imidazol-1-ylmethyl) -1, 3-dioxane-4-yl-, methoxyLphenyl) -benzyl imide. from m.p. 213, Example 4. A mixture of 1.8 parts of 4- (1-pyrrolidinyl) -phenol, 0.4 hours of a 78% dispersion of sodium hydride and 100 hours, of dimethyl sulfoxide is stirred for 1 hour at 40 ° C. Then 4.2 hours, cis-2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-ylmethyl-methanesulonate is added and stirring is continued overnight at . The reaction mixture is cooled and poured into water. The product is extracted with 1,1-oxybisethane. The extracts are washed twice with water, dried, filtered and evaporated. The residue is crystallized from 1,1-oxybisbutane. The product is filtered and dried. 2.3 hours (48%) of cis-1- 2- (2, 4-dichlorophenyl) (1-pyrrolidinyl) -phenoxymethyl-, 3-dioxolan-2-ylmethyl -1H-imidazole are obtained, m.p. 149.1 ° C. Example 5. A mixture of 1.9 h, 4- (4-morpholinyl) -phenol, 4.2 parts of CIS-2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-Dioxolan-4-ylmethyl-methanesulfonate, 2 parts of potassium carbonate and 80 parts of 4-methyl-2-pentanone are stirred and heated by reverse distillation overnight. Then the reaction mixture is cooled, water is added and the product is extracted twice 1,1-oxybisethane. The combined extracts are dried, filtered and evaporated. The residue is purified on a chromatographic column on silica gel, eluting with trichloromethane. Pure fractions are collected, the eluate is evaporated. The residue is crystallized from 1,1-oxybis of butane, obtained after drying 2.3 hours, (47%) of cis-4-4-2- (2, 4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) - 1,3-dioxolan-4-ylmethoxy-phenylJ-morpholine with m.p. Example b. A mixture of 1.9 parts of chlorine. Hydrate 4- (dimethylamino) -phenol, 4.2 h, cis-2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolane -4-ylmethyl-methanesulfonate, 4 parts of potassium carbonate and 80 hours. 4-methyl-2-pentanone is stirred with heating under reflux overnight. Then the reaction mixture is cooled, water is added and the product is extracted twice with 1,1-oxybisethane. The extracts are washed with water, dried, filtered and evaporated. The residue is converted to the ethanedioate salt in 2-propanone and 2,2-oxybispropane. The salt is filtered and crystallized from ethanol. 2.4 parts (37%) of cis-4- 2- (2, 4-dichlorophenyl) -2- (1H-imidazol-1-yl-mgtil) -l, 3-dioxolan-4-ylmethoxy -NN- dimethylbenzolamine with so pl. 112.5 s. Example 7. A mixture of 1, 8 parts of N- (4-hydroxyphenyl) propanamide, 4.2 parts of cis-2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-ylmethyl-methanesulfonate, 2 parts of potassium carbonate and 67.5 hours of N, N-dimethylformamide are stirred and heated overnight at 100 ° C. The reaction mixture is cooled and poured into water. The product is extracted twice with benzene. The combined extracts are washed with water, dried, filtered and evaporated. The residue is converted to the ethanedioate salt in 4-methyl-2-pentanone and 2,2-oxybispropane. The salt is filtered and dried during the day off at 80 ° C. 2.3 parts (37%) of 2-propanolate of cis-L-4-2- (2, 4-dichlorophenyl) -2- (1H-imidazrl-1-ylmethyl) -1,3-dioxolan-4- ylmethoxy-phenyl;) - propane-amide. M.p. 116.9 ° C. Example 8. A mixture of 1.7 h, N- (4-hydroxyphenyl) -acetamide, 4.2 h, cis-2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-yl-methanesulfonate, .2 parts of potassium carbonate and 69 hours, N, N-dimethylformamide is stirred overnight at 100 ° C. Then the reaction mixture is cooled and poured into water. The product is extracted twice with trichloromethane. The combined extracts are washed twice with water, dried, filtered and evaporated. The residue is triturated in a mixture of 4-methyl-2-pentanone and 2, 2-oxybispropane. The product is filtered and crystallized from 4-methyl-2-pentanone. 2.8 Chr (61%) cis-N-4- 2 - (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-ylmethoxy-phenyl) - acetamide with so pl. 180.5 ° C. A mixture of 8.9 h, cis-N-} 4-ts- (2, 4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-ylmethoxy-phenyl-acetamide, 1.5 h, hydroxides. potassium and 80 h, 1-butanol is stirred at heating with reverse distillation overnight. The reaction mixture is then evaporated and water is added to the residue. The precipitated product is filtered and crystallized from methylbenzene. 6.6 parts (82%) of CIS-4- 2- (2, 4-dichlorophenyl) -2- (1H-) nmidazol-1-ylmethyl) -1, 3-dioxolan-4-yl-methoxy 1-benolamine are obtained t, pl. 164 ,. Example 9. A. A mixture of 33.8, h, 4- (1-pinperazinyl).-Phenol dibromide, 1.2 h, acetic anhydride, 42 parts of potassium carbonate and AIA h, 1,4-dioxane is stirred with heating with the return distillation within 3 days. The reaction mixture is filtered and the filtrate is evaporated. The solid residue is stirred in water and sodium bicarbonate is added. The mixture is stirred for 30 minutes. The precipitated product is filtered and dissolved in dilute hydrochloric acid. The solution is extracted with trichloromethane. The acidic aqueous phase is separated and neutralized with ammonium hydroxide. The product is filtered and kirstallizut from ethanol. Obtain 5.7 h. 1-acetyl-4- {4-hydroxyphenyl) -pipa Razin with so pl. 181, B. A mixture of 2.4 parts of 1-acetyl-4- (4-ox phenyl) piperazine, 0.4 hours, 78% sodium hydride dispersion, 75 parts of dimethyl sulfoxide, and 22.5 hours, benzene is stirred for 1 h at 40 Then 4.2 h, cis-2- {2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1, 3-dioxolan-4-ylmethyl-methyl sulfonate and stirring continue overnight at 1CO ° C. The reaction mixture is then cooled and diluted with water. The product is extracted with 1,1-oxybisethane. The extract is dried, filtered and evaporated. The residue is crystallized from 4-methyl-2-penta tanon, the product is filtered and dried. 3.2 h- (59%) dis-1-acetyl-4- | 4- 2- (2, 4-dichlorophenyl) 8 -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolane are obtained. 4-ylmethoxy-phenyl-piperazine with mp. 146®С. Example 10. To a stirred solution of 3.6 parts of N- (4-hydroxyphenyl) -N-methylacetamide in 100 parts of dimethyl sulfoxide, 0.7 parts of a 78.78% sodium hydride dispersion was added and stirring continued until foam formation ceased. Then 3.4 parts of cis-2- (2,4-dichlorophenyl) -2- (1n-imidazol-1-ylmethyl) -1,3-dioxolan-4-ylmethyl-methanesulfonate are added and the whole mixture is stirred for 3 hours at. Then the reaction mixture is cooled and poured into water. The product is extracted with dichloromethane, the extract is washed with dilute hydrochloric acid, dried, filtered and evaporated. The residue is converted to the ethanedioate salt in 2-propanol. The salt is filtered and crystallized from 2-propanol. 9.2 parts of ethanedioate cis-M- | 4- 2- (2, 4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolano-4-ylmethoxy-phenyl-N- are obtained. Methylacetamide (1: 1) with mp. IC. Example 11. According to the procedure of Example 4, using equivalent amounts of the starting materials, the following compounds are obtained as free bases or as acid addition salts: - O (O O
Example 12. According to the procedure of Example 4, using equivalent amounts of the corresponding starting materials, the following compounds were prepared: cis-4- 2- (2,4-dichlorophenyl) -2- (1H-imidaeol-1-ylmethyl) -1.3- dioxolan-4 ylmethoxyj-2-nitrobenzene amine
mp 148.1 ° C; cis-ethyl-4- 2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-ylmethoxy-phenyl -1-piperazinecarboxylate dichlorohydrate with m, pl. 195.4 C.
Example 13. According to the procedure of Example 3, using equivalent amounts of the corresponding starting materials, the following compounds were obtained:
(E) -2-Butanedioate (2: 1) ethyl 4-54- 2- (1H-imidazol-1-ylmethyl) -2- (4-methoxyphenyl) -1, 3-dioxolan-4-ylmethoxy-phenyl -1 - piperazine-carboxylate with t, pl. 159,
1-acetyl-4- 4- 2- (1.H-imidazol-1-ylmethyl) -2- (4-methoxyphenyl) -1,3 dioxolan-4-ylmethoxy} phenyl1-piperazine with mp.171,
cis-ethyl 4- | 3- 2- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3 dioxolan-4-ylmethoxy-phenyl -1-piperazinecarboxylate with m.p.119, 5 ° C and
cis-1-acetyl-4- (2,4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-ylmethoxy1-phenylJ-piperazine dibromohydrate monohydrate with m. pl. 206, 5 ° C.
PRI me R 14. According to the procedure of Example 7, using equivalent amounts of the corresponding N- (hydroxyphenyl) acetamide instead of -N- (4; oxyphenyl) propanamide, we obtain: cis-N-J2-12- ( 2, 4-dichlorophenyl) -2- (1H-imidazol-1-ylmethyl) -1,3-dioxolan-4-ylmethoxy-phenyl acetamide with mp.183.6 C | and nitrate cis-N- | z - 2- (2,4-dichlorophenyl) -2t (1H-imidazol-1-ylmethyl) -1, 3-dioxolane-H-ylmethoxy-phenylJ-acetamide with so pl.
170.5 ° C.
Example; 15. A mixture of 2.2 hN- (5-hydroxy-2-nitrophenyl) -acetamide, 4.2-h-cis-2- (2, 4-dichlorophenyl) -2-.
- (1H-imidazol-1-ylmethyl) -1,3-dioxo (Lan-4-ylmethyl-methane sulfonate, 3 h ,.
potassium carbonate and 90 h, N, N-dimethylformamide are stirred and heated overnight at 120 C. Then the reaction mixture is cooled and poured. The product is extracted twice with dichloromethane, the combined extracts are washed twice with a solution of calla carbonate, dried, filtered and evaporated. The residue C1 is washed for 80 hours. methanol and add 2 hours, 30% sodium methoxide solution. The whole mixture was stirred under reflux for 1 hour. The mixture was then poured into water and the layers were separated. The organic phase is dried, filtered and evaporated. The residue is taken up in the hydrochloride salt in 2-propanol. The salt is filtered and crystallized from ethanol. 1.3 parts (25%) of cis-5-G2- (2/4-dichlorophenyl) -2- (1H-imidazol-1-yl-methyl-1) -1,3-dioxolan-4-ylmethoxy -2-nitrobenzenamine are obtained (25%) with t. pl. 242,
Example 16 According to the procedure of Example 15, using equivalent amounts of the corresponding starting materials, the following compounds were prepared:
IS
20
25
126.1
CH-J,
base 122.2
: CrH base 115.6
SNO-SNg-CH, base
0 CHCCHj), 116.3 base (CHj) -CH ,, 111.4 base (120.3 base CH (CH,) - CH2-CH, 100.5 base 176.4 CO-CHj base
5,152.1 SOj-CH base 107.1 CHj-CjHj base 134.1
6 "5 base
40

权利要求:
Claims (1)
[1]
1. A method for producing 1- (1,3-dioxolan-2-ylmethyl) -1H-imidazoles or -1H-1,2,4-triazoles derivatives of a general formula T
1G-
&
I-lchj-rO
where d is CH or N;
Agphenyl, substituted phenyl, containing 1–3 substituents from the group: halogen, lower alkyl or phenyl, 3s-substituted with a lower alkoxy group; the radical A represents an assembly:
a | amino radical of Formula: -N :;
where RJ and R. - independently of
another atom of a carol or lower alkyl; b) radical ;; formulas -. X is oxygen or sulfur; oxygen or o or 1, a hydrogen atom, lower alkyl, mono- or dihalide, lower alkyl, phenyl or substituted phenyl with 1–2 substituents, independently representing halogen, lower alkyl, or lower alkoxy at services , that: if X is sulfur, then Y is NW m 1, and if m 1, then R is different from hydrogen, / - .. c) is a radical of the formula -N. , where Z is a direct bond, or NR g where R 4 is a hydrogen atom, lower alkyl, lower alkyloxy, lower alkyl, lower alkanoyl, lower alkylsulfonyl, lower alkylrx carbonyl, lower alkyloxycarbonylmethyl, phenoxycarbonyl, phenyl, benzyl, benzoyl or substituted benzoyl with 1-2 substituents, we can prescribe independently halo, lower alkyl or lower alkyl; R is a hydrogen atom or a nitro group, provided that if R is a nitro group, then A is an amino group or their acid addition salts, as a mixture or individual stereoisomers, characterized in that the compounds of the general formula P are CHg-W 12 where / Q and Ag has the above meanings; W is a halogen, methylsulfonyloxy or 4-methylphenylsulfonyloxy group and is reacted with a compound of the general formula I | : / Ho-f: de A and R have the above values, an inert organic solvent at elevated temperatures and isolate the desired product in free form as a salt, as a mixture, or in specific age isomers. 2, Method POP.1, otlich. Yach and y. With the fact that the process is carried out at 100-130 ° C. .3. A method according to Claims 1 and 2, characterized in that the process is carried out in the presence of a base. Sources of information taken into account in the examination 1. US patent number 3936470, cl. C 07 O 233/60, 1976. The priority is on signs 01/31/77 r.: Q-CH, R-hydrogen atom, A is in position 4 of the phenyl ring and has the meanings given in the claims. 11/21/77 r.Slow.-N, R and A are as defined in the claims, Q-CH, R is as defined in the claims, A is in a position other than position 4 of the phenyl ring and has the values indicated in the claims.

类似技术:

公开号 | 公开日 | 专利标题

SU786899A3|1980-12-07|Method of preparing derivatives of 1-|-1h-imidazoles or -1h-1,2,4-triazoles or their acid-additive salts in the form of mixture or individual stereoisomers

EP2981520B1|2019-03-06|New process for the synthesis of 1-|thio)phenyl)piperazine

SU888821A3|1981-12-07|Method of preparing 5-|-oxazolidinones or their sulphur-containing analogs

US4360519A|1982-11-23|Analgesic method using a morpholine compound

US4517197A|1985-05-14|-N-substituted phenyl-5-methoxymethyl-2-oxazolidinones and pharmaceutical compositions containing same

WO1997017333A1|1997-05-15|Benzoxazine antimicrobial agents

FI74954C|1988-04-11|PROCEDURE FOR FRAMSTATION OF N-METHYL-N'-CYANO-N '' - / 2 | METHYLTHIO) ETHYL / GUANIDINE.

US3707477A|1972-12-26|1,1,1-trichloro-2-amido-2-amino-ethanes

AU4281399A|2000-01-05|Chemical synthesis of morpholine derivatives

EP0323799B1|1992-11-11|Imidazole derivatives ii

EP1015437B1|2003-12-03|Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals

KR850001318B1|1985-09-14|Process for preparing 1h-1,2,4-triazol derivatives

CA2066203A1|1992-01-18|Benzene derivatives substituted with heterocyclic ring, process for preparing same, and herbicides containing same as active ingredients

US9920070B2|2018-03-20|Spiro-oxazines, indolinones and preparation thereof

US3184460A|1965-05-18|1-|-2-imidazolinones, -2-imidazolidinones and -2-pyrimidinones

DK141287B|1980-02-18|Analogous process for the preparation of 5-nitro-imidazole carbamates or acid addition salts thereof.

FI78078B|1989-02-28|FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA P-OXO-OXAZOLINDINYLBENSENSULFONAMIDER.

Horvath et al.2013|Synthesis of some 1, 4-disubstituted thiosemicarbazides as intermediates for the synthesis of 1, 3, 4-thiadiazole derivatives

Sharma et al.2008|Synthesis of some novel ethoxyphthalimide derivatives of pyrazolo [3, 4-c] pyrazoles

JP4305747B2|2009-07-29|2-Phenyl-4- | imidazole compound

US4071684A|1978-01-31|Process for producing 3-substituted 1,2,4-triazines

US4777262A|1988-10-11|5-|-3-phenyl-3-|-2-methylisoxazolidine derivatives

IE61576B1|1994-11-16|Cyclobutene-3, 4-dione-intermediates and their use in the preparation of histamine H2-antagonists

Ogawa et al.1988|Studies on Positive Inotropic Agents. VI.: Synthesis of 1-Aromatic Ring Substituted 4-|-piperazine Derivatives

RU2292340C1|2007-01-27|Method for preparing r-methyl-derivatives of 3,5-diamino-1,2,4-triazole

同族专利:

公开号 | 公开日

AU3285078A|1979-08-09|

DK42678A|1978-08-01|

DK158042C|1990-08-13|

US4223036A|1980-09-16|

CH644118A5|1984-07-13|

IT1155800B|1987-01-28|

KE3270A|1983-05-13|

US4144346A|1979-03-13|

NO148643B|1983-08-08|

IE780195L|1978-07-31|

FI63398B|1983-02-28|

HU177646B|1981-11-28|

NZ186275A|1980-08-26|

NL188578C|1992-08-03|

IE46035B1|1983-01-26|

LV5015A3|1993-06-10|

FI780294A|1978-08-01|

YU22178A|1983-01-21|

NL7801048A|1978-08-02|

PT67600B|1980-01-14|

NO780335L|1978-08-01|

ZA78548B|1979-09-26|

FR2378778B1|1981-07-24|

SE7801088L|1978-08-01|

DE2804096A1|1978-08-03|

FI63398C|1983-06-10|

GB1594859A|1981-08-05|

SE439773B|1985-07-01|

PH14635A|1981-10-12|

IL53923A|1981-06-29|

IT7847837D0|1978-01-30|

YU40319B|1985-12-31|

ATA63678A|1981-09-15|

FR2378778A1|1978-08-25|

HU184842B|1984-10-29|

CA1094559A|1981-01-27|

IL53923D0|1978-04-30|

PT67600A|1978-02-01|

MY8400209A|1984-12-31|

BE863382A|1978-07-27|

JPS5395973A|1978-08-22|

NO148643C|1983-11-16|

NL188578B|1992-03-02|

CS194833B2|1979-12-31|

US4358449A|1982-11-09|

JPS6257634B2|1987-12-02|

GR62553B|1979-05-09|

DK158042B|1990-03-19|

AT366683B|1982-04-26|

US4335125A|1982-06-15|

PL113973B1|1981-01-31|

CY1192A|1983-10-07|

LU78960A1|1978-06-21|

AU521329B2|1982-03-25|

KR810000675B1|1981-06-20|

HK9182A|1982-03-05|

ES465981A1|1979-07-16|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

US3658797A|1968-08-06|1972-04-25|Lilly Co Eli|Novel 5-nitroimidazole antiparasitic agents|

US3575999A|1968-08-19|1971-04-20|Janssen Pharmaceutica Nv|Ketal derivatives of imidazole|

US4079062A|1974-11-18|1978-03-14|Janssen Pharmaceutica N.V.|Triazole derivatives|

US3936470A|1975-01-27|1976-02-03|Janssen Pharmaceutica N.V.|1,3-Dioxolan-2-ylmethylimidazoles|

CA1065873A|1975-01-27|1979-11-06|Janssen Pharmaceutica Naamloze Vennootschap|Imidazole derivatives|

US4144346A|1977-01-31|1979-03-13|Janssen Pharmaceutica N.V.|Novel 1--1H-imidazoles|

US4160841A|1977-01-31|1979-07-10|Janssen Pharmaceutica, N.V.|Heterocyclic derivatives of 1--1H-imidazoles|

US4160838A|1977-06-02|1979-07-10|Janssen Pharmaceutica N.V.|Antimicrobial and plant-growth-regulating triazole derivatives|US4232034A|1977-01-31|1980-11-04|Janssen Pharmaceutica, N.V.|Heterocyclic derivatives of 1--1H-imidazoles|

US4229460A|1977-01-31|1980-10-21|Janssen Pharmaceutica N.V.|Heterocyclic derivatives of 1--1H-1,2,4-triazoles having antifungal and antibacterial properties|

US4244964A|1977-01-31|1981-01-13|Janssen Pharmaceutica N.V.|Heterocyclic derivatives of 1--1H-1,2,4-triazoles|

US4144346A|1977-01-31|1979-03-13|Janssen Pharmaceutica N.V.|Novel 1--1H-imidazoles|

US4368200A|1978-06-23|1983-01-11|Janssen Pharmaceutica N.V.|Heterocyclic derivatives of -methyl-1H-imidazoles and 1H-1,2,4-triazoles|

US4267179A|1978-06-23|1981-05-12|Janssen Pharmaceutica, N.V.|Heterocyclic derivatives of methyl-1H-imidazoles and 1H-1,2,4-triazoles|

US4490530A|1981-01-14|1984-12-25|Janssen Pharmaceutica N.V.|Heterocyclic derivatives of -methyl-1H-imidazoles and 1H-1,2,4-triazoles|

EP0006722B1|1978-07-03|1984-09-05|Janssen Pharmaceutica N.V.|Derivatives of -1.3-dioxolan-2-ylmethyl)-1h-imidazoles and -1h-1.2.4-triazoles, their preparation and use as fungicides and bactericides|

US4287195A|1978-07-14|1981-09-01|Janssen Pharmaceutica, N.V.|Heterocyclic derivatives of [4--1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles|

US4338327A|1978-10-06|1982-07-06|Janssen Pharmaceutica, N.V.|Substituted 1--1H-1,2,4-triazoles|

US4503055A|1979-03-26|1985-03-05|Janssen Pharmaceutica, N.V.|Derivatives of [4--1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles|

DE3039087A1|1980-10-16|1982-05-19|Hoechst Ag, 6000 Frankfurt|1--AZOLES, THEIR SALTS, METHOD FOR THE PRODUCTION AND THEIR USE|

DE3104311A1|1981-02-07|1982-08-19|Bayer Ag, 5090 Leverkusen|2-AZOLYLMETHYL-1,3-DIOXOLANE AND -DIOXANE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS FUNGICIDES|

US4490540A|1981-09-14|1984-12-25|Janssen Pharmaceutica N.V.|azole derivatives|

US4375474A|1982-02-11|1983-03-01|SyntexInc.|Dioxalane containing imidazole compounds, compositions and use|

US4491588A|1982-03-31|1985-01-01|University Of Tennessee Research Corporation|Treatment of psoriasis and seborrheic dermatitis with imidazole antibiotics|

US4942162A|1982-03-31|1990-07-17|University Of Tennessee Research Corporation|Topical treatment of seborrheic dermatitis with ketoconazole|

US4569935A|1983-03-17|1986-02-11|University Of Tennessee Research Corp.|Topical treatment of psoriasis with imidazole antibiotics|

EP0094052A3|1982-05-12|1984-07-18|Hoechst Aktiengesellschaft|1--1h-imidazoles and -1h-1,2,4-triazoles and their salts, process for their preparation, compositions containing them and their use|

JPH0441147B2|1983-01-28|1992-07-07|Yoshiki Hamada|

US4619931A|1983-02-28|1986-10-28|Janssen Pharmaceutica, N.V.|[[4-[4-phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles|

US4735942A|1984-01-09|1988-04-05|Janssen Pharmaceutica, N.V.|[[4-[4-phenoxymethyl]-1,3-dioxolan-2-yl]-methyl]-1H-imidazoles and 1H-1,2,4-triazoles having antimicrobial properties|

EP0121081B1|1983-03-03|1991-01-30|BASF Aktiengesellschaft|Azolylmethylcycloalkanes, process for their preparation and their therapeutical use|

DE3308554A1|1983-03-10|1984-09-13|Hoechst Ag, 6230 Frankfurt|1- / 1,3-DIOXOLAN-2-YLMETHYL) -AZOLE, THEIR SALTS, METHOD FOR THE PRODUCTION AND THEIR USE|

DE3401694A1|1984-01-19|1985-07-25|Basf Ag, 6700 Ludwigshafen|AZOLYLMETHYLCYCLOACETALE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|

DE3404819A1|1984-02-10|1985-08-14|Ludwig Heumann & Co GmbH, 8500 Nürnberg|NEW 1,3-DIOXOLANYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCT CONTAINING THESE COMPOUNDS|

EP0165781A1|1984-06-18|1985-12-27|Eli Lilly And Company|Aromatase inhibiting N-substituted imidazole derivatives|

DK354185A|1984-08-31|1986-03-01|Hoffmann La Roche|1,3-dioxolane derivatives|

US4661602A|1985-03-29|1987-04-28|G. D. Searle & Co.|Substituted alkyl imidazole derivatives|

US4628104A|1985-04-08|1986-12-09|G. D. Searle & Co.|Imidazole ketone derivatives|

US4761483A|1985-06-26|1988-08-02|G. D. Searle & Co.|Chloro-substituted ketone imidazole derivatives|

US4791111A|1985-12-23|1988-12-13|Janssen Pharmaceutica, N.V.|[[4-[4-phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties|

FR2593816B1|1986-02-04|1989-02-10|Ire Celltarg Sa|IMIDAZOLE DERIVATIVES, PREPARATION METHOD AND FUNGICIDAL COMPOSITIONS CONTAINING THEM|

DE3609596A1|1986-03-21|1987-10-01|Hoechst Ag|2-AZOLYLMETHYL-2-ARYL-1,3-DIOXOLANE AND THE SALTS THEREOF, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING IT AND THEIR USE|

DE3609598A1|1986-03-21|1987-10-01|Hoechst Ag|2-AZOLYLMETHYL-2-ARYL-1,3-DIOXOLANE AND THE SALTS THEREOF, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING IT AND THEIR USE|

DE3609597A1|1986-03-21|1987-10-01|Hoechst Ag|2-AZOLYLMETHYL-2-ARYL-1,3-DIOXOLANE AND THE SALTS THEREOF, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING IT AND THEIR USE|

DE3622791A1|1986-07-07|1988-01-21|Heumann Pharma Gmbh & Co|NEW 1,4-PIPERAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AND MEDICINAL PRODUCT CONTAINING THESE COMPOUNDS|

US4788190A|1986-12-24|1988-11-29|Schering Corporation|2,4,4-tri- and 2,2,4,4-tetra substituted-1,3-dioxolane antifungal, antiallergy compounds|

CA1331757C|1988-02-29|1994-08-30|Janssen Pharmaceutica Naamloze Vennootschap|5-lipoxygenase inhibiting 4-phenols|

AU614818B2|1988-03-28|1991-09-12|Janssen Pharmaceutica N.V.|2-imidazolylmethyl-1,3-dioxolanyl methylthiophenyl carbamate derivatives and their use as antineoplastic agents|

US4992421A|1988-04-19|1991-02-12|Abbott Laboratories|Luteinizing hormone releasing hormone antagonist|

GB8910069D0|1989-05-03|1989-06-21|Janssen Pharmaceutica Nv|Method of topically treating acne vulgaris|

GB9014221D0|1990-06-26|1990-08-15|Janssen Pharmaceutica Nv|Method of treating alopecia|

US5158949A|1990-12-20|1992-10-27|SyntexInc.|1,3-dioxolane derivatives as cholesterol-lowering agents|

DK0630228T3|1992-03-20|1998-06-02|Janssen Pharmaceutica Nv|Means for regulating skin fatness|

US6022532A|1993-03-12|2000-02-08|Janssen Pharmaceutica, N.V.|Agent for regulating the greasiness of the skin|

US5641494A|1992-03-20|1997-06-24|Janssen Pharmaceutica N.V.|Agent for regulating the greasiness of the skin|

US5274108A|1992-06-18|1993-12-28|SyntexInc.|Process for preparing 1,3-dioxolane derivatives|

AU5955094A|1992-12-22|1994-07-19|Sepracor, Inc.|Methods and compositions ofketoconazole for treating fungal yeast and dermatophyte infections|

WO1994014446A1|1992-12-22|1994-07-07|Sepracor, Inc.|Methods and compositions ofketoconazole for treating fungal, yeast and dermatophyte infections|

IL111584D0|1993-11-18|1995-01-24|Merck & Co Inc|Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them|

DE69426727D1|1993-12-23|2001-03-29|Procter & Gamble|ANTIMICROBIAL COMPOSITIONS FOR WIPES|

US5565478A|1994-03-14|1996-10-15|The United States Of America As Represented By The Department Of Health & Human Services|Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs|

TW460296B|1994-09-01|2001-10-21|Janssen Pharmaceutica Nv|Topical ketoconazole emulsion compositions without sodium sulfite|

GB9509631D0|1995-05-12|1995-07-05|Sandoz Ltd|Antifungal combination|

US5728834A|1996-11-14|1998-03-17|Wyckoff Chemical Company, Inc.|Process for preparation of 4-aryl-1,2,4-triazol-3-ones|

BR9810396A|1997-07-02|2000-09-05|Neutrogena Corp|Processes for using compositions containing dichlorophenyl imidazoldioxolane to treat seborrheic dermatitis, dandruff, psoriasis and acne, and compositions thereof|

ES2141667B1|1997-11-04|2000-11-16|Sint Quimica Sa|CIS PREPARATION PROCEDURE- 1--2--1,3-DIOXOLAN- 4-IL) METOXI) PHENYL) -4-PIPERAZINE.|

US7767203B2|1998-08-07|2010-08-03|Ganeden Biotech, Inc.|Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption|

US6461607B1|1998-08-24|2002-10-08|Ganeden Biotech, Inc.|Probiotic, lactic acid-producing bacteria and uses thereof|

KR20000051143A|1999-01-19|2000-08-16|김충섭|Novel azole derivatives having a fluorinated vinyl group and a process for the preparation thereof|

US6080744A|1999-02-10|2000-06-27|Ayon-Covarrubias; Blas|Topical antifungal treatment|

US6812238B1|1999-11-02|2004-11-02|Basilea Pharmaceutica Ag|N-substituted carbamoyloxyalkyl-azolium derivatives|

US6673373B2|2001-02-01|2004-01-06|Carlsbad Technology Inc.|Antifungal formulation and the methods for manufacturing and using the same|

CA2442281C|2001-03-27|2010-06-08|GalenLimited|Intravaginal drug delivery devices for the administration of an antimicrobial agent|

US20030236259A1|2002-02-05|2003-12-25|Rolf Hohlweg|Novel aryl- and heteroarylpiperazines|

WO2003066604A2|2002-02-05|2003-08-14|Novo Nordisk A/S|Novel aryl- and heteroarylpiperazines|

US8404751B2|2002-09-27|2013-03-26|Hallux, Inc.|Subunguicide, and method for treating onychomycosis|

JP4680903B2|2003-07-29|2011-05-11|ハイ・ポイント・ファーマスーティカルズ、エルエルシー|Pyridazinyl-piperazine and their use as histamine H3 receptor ligands|

US20050074494A1|2003-10-06|2005-04-07|Xiu-Xiu Cheng|Itraconazole immediate release formulation|

ES2375929T3|2005-07-04|2012-03-07|High Point Pharmaceuticals, Llc|HISTAMINE RECEIVER ANTAGONISTS H3.|

EP2038256A1|2006-05-23|2009-03-25|TransTech Pharma, Inc|6--2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament|

EP2402324A1|2006-05-29|2012-01-04|High Point Pharmaceuticals, LLC|Benzodioxolylcyclopropylpiperazinylpyridazines|

US20080161324A1|2006-09-14|2008-07-03|Johansen Lisa M|Compositions and methods for treatment of viral diseases|

WO2008042898A2|2006-10-02|2008-04-10|Cortendo Invest, Ab|Ketoconazole enantiomer in humans|

EP2014656A3|2007-06-11|2011-08-24|High Point Pharmaceuticals, LLC|New heteocyclic h3 antagonists|

PL2211626T3|2007-08-29|2020-03-31|Ganeden Biotech, Inc.|Baked goods|

PL2638807T3|2007-10-16|2021-08-23|Ganeden Biotech, Inc.|Beverage compositions|

EP2285351A2|2008-04-15|2011-02-23|Schering Corporation|Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas|

EP2278957A2|2008-04-15|2011-02-02|Schering Corporation|Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas|

US7788209B2|2008-05-05|2010-08-31|United Technologies Corporation|Hybrid fault reasoning and guided troubleshooting system that uses case-based reasoning and model-based reasoning|

JP2009286756A|2008-05-30|2009-12-10|Fujifilm Finechemicals Co Ltd|Triazole derivative or salt thereof|

CN101302213B|2008-06-30|2012-07-25|寿光富康制药有限公司|Preparation of cis-2--2--[1,3] dioxolane -4-Methyl methanesulfonate|

CN101665490B|2008-09-01|2012-01-04|浙江东亚药业有限公司|Method for preparing ketoconazole derivatives|

CA2740423C|2008-10-16|2020-09-08|Ganeden Biotech, Inc.|Probiotic grain-based compositions|

EP3246039A1|2009-04-29|2017-11-22|Ganeden Biotech, Inc.|Bacterial cell membrane formulation|

CN101993436B|2010-10-29|2012-06-27|杭州欧拓普生物技术有限公司|Method for preparing imidazole antifungal medicine derivate|

CN102070620B|2011-01-25|2012-12-12|南京白敬宇制药有限责任公司|Preparation method of antibacterial ester|

WO2012135499A1|2011-03-31|2012-10-04|Ganeden Biotech, Inc.|Probiotic sports nutrition compositions|

CN102627633A|2012-03-21|2012-08-08|浙江丽晶化学有限公司|New method for purifying elubiol|

US8530409B1|2012-06-12|2013-09-10|Dipexium Pharmaceuticals LLC|Stable pexiganan formulation|

CA2898574A1|2013-02-06|2014-08-14|Cortendo Ab |Novel functionalized 4--1,3-dioxolane analogs exhibiting cytochrome p450 inhibition and their method of use|

CN105377355A|2013-03-14|2016-03-02|拇趾公司|Method of treating infections, diseases or disorders of nail unit|

CN104447711A|2013-09-23|2015-03-25|南京白敬宇制药有限责任公司|Method for synthesizing ketoconazole|

EP3049084A4|2013-09-25|2017-03-15|Cortendo AB |Novel functionalized 5--1,3-dioxane analogs exhibitng cytochrome p450 inhibition|

US10149848B2|2015-12-09|2018-12-11|Cipla Limited|Method for the treatment of bladder cancer|

EP3558304A2|2016-12-23|2019-10-30|Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt |Inhibitors of cytochrome p450 family 7 subfamily b member 1for use in treating diseases|

US20200215074A1|2017-06-22|2020-07-09|Cipla Limited|Method of Treatment of Cancer|

AU2019288677A1|2018-06-21|2021-01-14|Yumanity Therapeutics, Inc.|Compositions and methods for the treatment and prevention of neurological disorders|

法律状态:

优先权:

申请号 | 申请日 | 专利标题

US76426377A| true| 1977-01-31|1977-01-31|

US05/853,728|US4144346A|1977-01-31|1977-11-21|Novel 1--1H-imidazoles|LV920186A| LV5015A3|1977-01-31|1992-11-09|Method of obtaining 1--1H-imidazole or derivatives of 1H-1,2,4-triazole or their additive islands as a mixture or separate product|

[返回顶部]